Human PSC-Derived SAN-Plexus Assembloids: Innovations in Modeling Pacemaker Maturation

Study Background and Research Question

The human sinoatrial node (SAN) serves as the primary pacemaker of the heart, initiating and regulating heartbeat through complex neuro-cardiac signaling. While animal models have provided insights into SAN development and autonomic regulation, translating these findings to humans remains challenging due to significant interspecies differences and limited access to native human SAN tissue. There is a critical need for robust human in vitro systems that recapitulate the intricate interactions between pacemaker cells and their intrinsic cardiac neural inputs. The reference study, "Human PSC-derived sinoatrial node-cardiac plexus assembloids model innervation-associated maturation of pacemaker systems", addresses this gap by developing a platform to interrogate neuron-to-pacemaker signaling in human cardiac tissue.

Key Innovation from the Reference Study

The core innovation lies in creating a human in vitro model that integrates three elements: pluripotent stem cell-derived SAN organoids (SANOs), cardiac ganglionated plexus organoids (CGPOs), and atrial-like cardiac organoids. This tri-assembloid system mirrors the spatial and functional organization of the human SAN and its associated cardiac plexus. Importantly, the study leverages spatial transcriptomics to map the molecular landscape of the human SAN and uses this information to guide the assembly and interpretation of in vitro models. The platform's ability to recapitulate neural modulation of pacemaker activity—including disease-relevant conduction defects—represents a significant advance for cardiovascular research and drug discovery.

Methods and Experimental Design Insights

The researchers employed directed differentiation protocols to generate SANOs and CGPOs from human pluripotent stem cells (hPSCs). The SANOs were characterized by expression of pacemaker-specific transcription factors (SHOX2, ISL1, TBX3) and ion channels (HCN4), while CGPOs recapitulated features of intrinsic cardiac neurons. These components were then integrated with atrial-like cardiac organoids to form assembloids that support pacemaker-to-atrial conduction. Electrophysiological analyses demonstrated that the assembloids display spontaneous rhythmic activity and respond to neural modulation, providing a functional readout of neuron-pacemaker interactions. Spatial transcriptomics of human SAN tissue was used to validate the in vitro findings and to identify critical signaling pathways involved in pacemaker maturation.

Core Findings and Why They Matter

The assembled SAN-plexus organoids exhibited molecular, structural, and electrophysiological hallmarks of human pacemaker tissue. A major discovery was the identification of a neuron-to-pacemaker signaling axis involving CGPO-derived prosaposin (PSAP) and the SAN-enriched GPR37 receptor. Functional interrogation showed that PSAP-GPR37 signaling promotes the maturation of SAN-like pacemaker cells, linking neural input directly to functional development. This mechanism was further supported by spatial transcriptomic mapping of patient-derived SAN tissue, highlighting its physiological relevance. The platform also enabled modeling of disease states, including conduction block and arrhythmogenic dysfunction, underscoring its translational potential for studying inherited and acquired SAN disorders.

Comparison with Existing Internal Articles

Several recent resources contextualize and extend the findings of this study. The article "Modeling Human SAN-Plexus Interactions with PSC-Derived Assembloids" provides a protocol-focused overview, emphasizing the fidelity of this human-specific system for dissecting neuro-cardiac signaling and conduction disorders. Another piece, "Isoproterenol Sulfate Dihydrate in Human Cardiac Assembloids", highlights the application of beta-adrenergic agonists such as Isoproterenol sulfate dihydrate to modulate and interrogate beta-adrenergic receptor signaling within these assembloid platforms, offering guidance on assay design and troubleshooting. Collectively, these articles reinforce the reference study's contribution by providing actionable protocols and expanding on the application of pharmacological tools for mechanistic studies.

Limitations and Transferability

Despite these advances, several limitations warrant consideration. First, while the assembloid system closely models human SAN-plexus interactions, it cannot fully replicate the three-dimensional architecture and complex in vivo innervation patterns present in the intact human heart. The differentiation protocols, though robust, may not capture the full diversity of pacemaker or neuronal subtypes. Disease modeling in this system primarily reflects cell-intrinsic and local circuit mechanisms, and may not account for systemic influences or chronic disease progression. Finally, the transferability of these findings to in vivo human physiology and large-scale drug screening requires further validation and optimization.

Protocol Parameters

• hPSC differentiation: Use established protocols for generating SANOs (SHOX2+, ISL1+, TBX3+; HCN4+) and CGPOs, optimizing for cellular heterogeneity and yield.
• Assembloid integration: Combine SANOs with CGPOs and atrial-like cardiac organoids in a 3D matrix to support pacemaker-to-atrial conduction.
• Electrophysiological interrogation: Employ multi-electrode array or patch-clamp techniques to assess spontaneous activity and neural modulation effects.
• Pharmacological modulation: For beta-adrenergic receptor signaling studies, treat assembloids with titrated concentrations of Isoproterenol hemisulfate, assessing dose-response and chronotropic effects (see protocol recommendations).
• Spatial transcriptomics validation: Align gene expression profiles from assembloids with reference human SAN tissue to confirm cellular identity and maturation state.

Research Support Resources

For researchers aiming to dissect beta-adrenergic or GPCR signaling in SAN-plexus assembloid models, Isoproterenol sulfate dihydrate (SKU C6402) provides a reliable, high-purity beta-adrenergic agonist suitable for protocol-driven studies. The compound's well-characterized solubility, stability, and receptor selectivity enable precise modulation of beta-adrenergic pathways in cardiovascular research workflows, as outlined in recent internal guides. For further reading on workflow integration and assay design, see this article on human pacemaker system maturation.